Clinical Trial Update: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years [Phase 3]

View source ↗

Summary

This is a Phase 3B open-label study evaluating the safety, tolerability, and immunogenicity of the Novartis Meningococcal B Recombinant Vaccine in healthy infan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• Novartis Meningococcal B Recombinant Vaccine (recombinant meningococcal B vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Status: COMPLETED | Results posted: 2016-01-20